HSP90AA1 and neoplasm: Previous data from Workman's research group has shown that downregulation of hAHA1 results in increased tumor sensitivity to the first generation Hsp90 inhibitor, Tanespimycin (17-N-allylamino-17-demethoxygeldanamycin, 17-AAG) (Holmes et al., 2008).